The Street Assesses AbbVie
This article was originally published in The Pink Sheet Daily
Executive Summary
With a market cap of a Bristol-Myers or Eli Lilly, AbbVie is worth more in early trading than the remaining Abbott. If it can keep growing Humira sales while making its pipeline pay-off, it will be the poster child for slimmed-down and refashioned pharma.
You may also be interested in...
Uptick In 4Q 2013 M&A Deal-Making Likely To Continue Into 2014, PwC Report Predicts
Earn-outs and other deal tools help bridge value gaps and share risk, enabling more deals to be finalized, report says. However, pharma is seeing increased M&A competition from biotechs looking to diversify and increase scale.
AbbVie Sets Out To Win Over Investors In Its First Financial Call
Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.
AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program
AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.